Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease
- PMID: 14747389
- DOI: 10.1097/01.asn.0000110181.64655.6c
Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease
Abstract
High serum total homocysteine (tHcy) is gaining scrutiny as a risk factor for cardiovascular disease in the general population. The relationship between tHcy and mortality and cardiovascular events in patients with end-stage renal disease (ESRD) is unsettled. This randomized trial evaluates the efficacy of high-dose folic acid in preventing events in ESRD. A total of 510 patients on chronic dialysis were randomized to 1, 5, or 15 mg of folic acid contained in a renal multivitamin with a median follow-up of 24 mo. Mortality, cardiovascular events, and homocysteine levels were assessed. There were 189 deaths, and 121 patients experienced at least one cardiovascular event. Composite rates of mortality and cardiovascular events among the folic acid groups did not differ (at 24 mo: 43.7% in 1 mg group, 38.6% in 5 mg group, 47.1% in 15 mg group; log-rank P = 0.47). Unexpectedly, high baseline tHcy was associated with lower event rates. From lowest to highest quartile, event rates at 24 mo were 54.5% for Q1, 41.8% for Q2, 41.2% for Q3, and 34.7% for Q4 (log-rank P = 0.033). In contrast to some studies describing tHcy as a risk factor for mortality and cardiovascular events, this study found a reverse relationship between tHcy and events in ESRD patients. Administration of high-dose folic acid did not affect event rates.
Similar articles
-
Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial.Am Heart J. 2006 Sep;152(3):448.e1-7. doi: 10.1016/j.ahj.2006.03.004. Am Heart J. 2006. PMID: 16923411 Clinical Trial.
-
Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.JAMA. 2007 Sep 12;298(10):1163-70. doi: 10.1001/jama.298.10.1163. JAMA. 2007. PMID: 17848650 Clinical Trial.
-
Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial.J Am Coll Cardiol. 2006 Mar 21;47(6):1108-16. doi: 10.1016/j.jacc.2005.10.064. Epub 2006 Feb 23. J Am Coll Cardiol. 2006. PMID: 16545638 Clinical Trial.
-
The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis.BMJ. 2012 Jun 13;344:e3533. doi: 10.1136/bmj.e3533. BMJ. 2012. PMID: 22695899 Free PMC article. Review.
-
Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients.Semin Dial. 2007 Nov-Dec;20(6):523-9. doi: 10.1111/j.1525-139X.2007.00336.x. Semin Dial. 2007. PMID: 17991198 Review.
Cited by
-
Food-Derived Uremic Toxins in Chronic Kidney Disease.Toxins (Basel). 2023 Feb 1;15(2):116. doi: 10.3390/toxins15020116. Toxins (Basel). 2023. PMID: 36828430 Free PMC article. Review.
-
Indoxyl sulfate, homocysteine, and antioxidant capacities in patients at different stages of chronic kidney disease.Nutr Res Pract. 2022 Aug;16(4):464-475. doi: 10.4162/nrp.2022.16.4.464. Epub 2021 Dec 2. Nutr Res Pract. 2022. PMID: 35919290 Free PMC article.
-
Homocysteine-Lowering Interventions in Chronic Kidney Disease.J Res Pharm Pract. 2021 Dec 25;10(3):114-124. doi: 10.4103/jrpp.jrpp_75_21. eCollection 2021 Jul-Sep. J Res Pharm Pract. 2021. PMID: 35198504 Free PMC article. Review.
-
Folic Acid and Vitamin B12 Administration in CKD, Why Not?Nutrients. 2019 Feb 13;11(2):383. doi: 10.3390/nu11020383. Nutrients. 2019. PMID: 30781775 Free PMC article. Review.
-
Circulating long noncoding RNA DKFZP434I0714 predicts adverse cardiovascular outcomes in patients with end-stage renal disease.Int J Cardiol. 2019 Feb 15;277:212-219. doi: 10.1016/j.ijcard.2018.08.013. Epub 2018 Aug 7. Int J Cardiol. 2019. PMID: 30097337 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical